De Novo device
BONEBRIDGE System, SAMBA 2 BB, SYMFIT 8.0, SAMBA 2 GO, SAMBA 2 Remote
Med-El Elektromedizinische Geraete GmbH · Active Implantable Bone Conduction Hearing System (PFO, Class II) · First FDA decision Jul 20, 2018, newest Jul 29, 2020Hearing loss
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
De Novo pathway
Device trials
5
Naming "BONEBRIDGE"
MAUDE reports
496
Brand "BONEBRIDGE", since 2015
PubMed studies
248
Mentioning "BONEBRIDGE"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing BONEBRIDGE System, SAMBA 2 BB, SYMFIT 8.0, SAMBA 2 GO, SAMBA 2 Remote
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
K200504 · Decided Jul 29, 2020 · 149 days after receipt
Device type: Active Implantable Bone Conduction Hearing System (PFO) · Otolaryngology (ENT)
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "BONEBRIDGE", any status and sponsor, newest update first.
- Expanded Indications in the Pediatric BONEBRIDGE PopulationActive, not recruiting
Med-El CorporationNot on our public-company list
NCT05615649 · 36 participants · Start Oct 3, 2023 · Primary completion Oct 2026
Device: MED-EL BONEBRIDGE Bone Conduction Implant · For: Hearing Loss, Conductive; Hearing Loss, Mixed
Sites: Aurora, Colorado; Miami, Florida; Newark, New Jersey · 6 sites in all
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "BONEBRIDGE", and for the whole product code for context.
This brand
496 reports: 321 malfunction, 175 injury, 0 death
Whole product code PFO
3,616 reports: 378 malfunction, 3,236 injury, 1 death
Newest reports for this brand
- BonebridgeMalfunction
MED-EL Elektromedizinische Geraete GmbH
9710014-2026-01001 · Received Oct 30, 2026
Device type: Active Implantable Bone Conduction Hearing System (PFO)
Device problem as coded: No Device Output
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "BONEBRIDGE"[tiab]. The summary above synthesizes these.
- Osseointegrated Auditory Devices: Bonebridge.
Miller ME · Otolaryngol Clin North Am · 2019Review
- Active Bone Conduction Prosthesis: Bonebridge(TM).
Zernotti ME, Sarasty AB · Int Arch Otorhinolaryngol · 2015Review
- [Clinical research progress of bonebridge implantation].
Wang Q, Guo Y, Xu B · Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2022Review
- Who's afraid of Dura Mater?
Zernotti ME, Gavilán J · Braz J Otorhinolaryngol · 2025
- Advances in auditory implants.
Iwasaki S · Auris Nasus Larynx · 2023Review
- The Bonebridge Bone Conduction Hearing Implant: indication criteria, surgery and a systematic review of the literature.
Sprinzl GM, Wolf-Magele A · Clin Otolaryngol · 2016Systematic Review
- The Bonebridge BCI 602 Active Transcutaneous Bone Conduction Implant in Children: Objective and Subjective Benefits.
Cywka KB, Skarżyski H, Król B, et al. · J Clin Med · 2021
- Bonebridge implants versus atresiaplasty in children with unilateral congenital aural atresia: A comparison study of audiological outcomes.
Zhu J, Liu Y, Wang Y, et al. · Int J Pediatr Otorhinolaryngol · 2024Comparative Study
- Evaluation of the Bonebridge BCI 602 active bone conductive implant in adults: efficacy and stability of audiological, surgical, and functional outcomes.
Cywka KB, Skarzynski PH, Krol B, et al. · Eur Arch Otorhinolaryngol · 2022
- [Setting up a "Bonebridge"].
Clarós P, Diouf MS, Clarós A · Rev Laryngol Otol Rhinol (Bord) · 2012Case Reports, English Abstract
- Bonebridge Bone Conduction Implant.
Bento RF, Lopes PT, Cabral Junior Fda C · Int Arch Otorhinolaryngol · 2015
- Paediatric Bonebridge: bilateral simultaneous asymmetrical implantation.
Dusu K, Walsh M, Eze N · J Laryngol Otol · 2019Case Reports
Other devices of this type
Also filed under product code PFO.
- Cochlear Osia® 3(I) Sound ProcessorCochlear Americas · 510(k) 2026
- Sentio Ti Implant KitOticon Medical AB · 510(k) 2024
- Cochlear Osia SystemCochlear Americas · 510(k) 2024
- Cochlear Osia® SystemCochlear · 510(k) 2023
- Cochlear Osia 2 SystemCochlear Americas · 510(k) 2022
- BCI 602 Lifts (1 mm)Med-El Elektromedizinische Geraete GmbH · 510(k) 2020
- Cochlear Osia OSI200 ImplantCochlear Americas · 510(k) 2019
- Cochlear Osia OSI100 ImplantCochlear Americas · 510(k) 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.